NCT00647790已完成不适用
PET Using Hormone Receptor Ligands in Breast Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 79
- 试验地点
- 1
- 主要终点
- To use estrogen-like ligands labeled with positron emitters to preoperatively evaluate the estrogen receptor (ER) status of breast cancer on PET imaging.
研究概览
简要总结
The purpose of this study is to find a way to learn the hormone receptor status of a tumor before surgery is done. By testing for the hormone receptor proteins, doctors can find out if the breast cancer uses hormones to grow. This is important since the hormone receptor status of a tumor helps doctors decide if extra treatment like chemotherapy or pills are needed.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and Female patients
- •Aged 18 or older at the time of breast cancer diagnosis
- •Patients with invasive breast cancer at least 1 cm in size. Patients who have had a prior surgical excision are eligible provided there is a residual of at least a 1 cm area suspected on imaging studies.
- •Histopathologic review at MSKCC confirming diagnosis of invasive breast cancer (ductal, lobular, or inflammatory breast cancer).
- •Patients who are operative candidates. Patient will have surgery to include either mastectomy or lumpectomy. Radiologic assisted excisions such as needle localization are also eligible.
- •Patients with bilateral breast cancer are eligible.
- •Patients with metastatic cancer, provided they need surgical biopsy.
- •Patients who are undergoing sentinel node mapping (day before or sameday mapping).
- •Patient must sign informed consent.
排除标准
- •Previous or concurrent malignancy (except basal and squamous skin cancer and stage 0 cervical cancer)
- •Patients who are pregnant or nursing
- •Patients unable to tolerate PET or PET/CT
- •Patients with known active infection, autoimmune or inflammatory disease such as sarcoidosis, and rheumatoid arthritis.
- •Patients with non invasive breast cancer such as DCIS.
- •Patients who have received prior radiation therapy to the affected breast.
- •Patients who have received prior chemotherapy, including neoadjuvant chemotherapy or hormonal therapy for breast cancer.
- •Patients living in a residential care or correctional facility.
结局指标
主要结局
To use estrogen-like ligands labeled with positron emitters to preoperatively evaluate the estrogen receptor (ER) status of breast cancer on PET imaging.
时间窗: conclusion of the study
次要结局
- To correlate ER positivity on PET ligand imaging, and conventional immunohistochemical pathologic analysis of ER positivity in surgical specimens.(conclusion of the study)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted TherapiesHER2-positive Breast CancerNCT04288141King's College London40
已完成
不适用
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast CancerBreast CancerNCT00362973University of Washington42
已完成
不适用
Studying Biopsy Samples in Women Undergoing First-Line Chemotherapy for Metastatic Breast CancerBreast CancerNCT00870168Centre Jean Perrin60
已完成
早期 1 期
Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor StatusBreast CancerNCT01916122Memorial Sloan Kettering Cancer Center54
已完成
早期 1 期
89ZrTrastuzumab Breast Imaging With Positron Emission TomographyBreast CancerNCT02065609Washington University School of Medicine52